News & Views
Scientists test drug to dampen involuntary movements
Apr 13 2011
Revealed at the annual meeting of the American Academy of Neurology, the study was written and conducted by Dr Ravi Anand, a consultant with Newron Pharmaceuticals in Italy.
The research spanned two years and was carried out with patients in the mid-to-late stages of the disease.
Of the 669 people taking part in the trial, some were given the new treatment safinamide and others took a placebo in order to ascertain the drug's effectiveness.
The safinamide was used in addition to levodopa and other dopaminergic treatments.
Showing that patients who took 100 milligrams of the new drug reduced movement issues by 24 per cent in those who scored four or higher on the scale prior to the start of the treatment, the tests demonstrated the drug had less impact at 50 milligrams.
"These results are an important step forward in understanding how safinamide impacts patients with severe Parkinson's disease," commented Dr Anand.
The American Academy of Neurology has over 22,000 members and its annual meeting took place in Honolulu on April 9th.
Digital Edition
Lab Asia 31.2 April 2024
April 2024
In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...
View all digital editions
Events
May 05 2024 Seville, Spain
InformEx Zone at CPhl North America
May 07 2024 Pennsylvania, PA, USA
May 14 2024 Oklahoma City, OK, USA
May 15 2024 Birmingham, UK
May 21 2024 Lagos, Nigeria